Wright Medical 8-K Net Sales and Adjusted EPS Exceed Previously Communicated Outlook Ranges

Exhibit 99

FOR RELEASE 3:00 P.M. CENTRAL
Thursday, October 29, 2009
Contact: John K. Bakewell
(901) 867-4527

Wright Medical Group, Inc. Reports Results for Third
Quarter Ended September 30, 2009

Net Sales and Adjusted EPS Exceed Previously Communicated Outlook Ranges

Strong U.S. Extremities Growth Continues with 24% Increase Over Prior Year

ARLINGTON, TN — October 29, 2009 — Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics, today reported financial results for its third quarter ended September 30, 2009.

Net sales totaled $117.7 million during the third quarter ended September 30, 2009, representing a 6% increase over net sales of $111.1 million during the third quarter of 2008. Foreign currency had no net impact on the Company’s third quarter 2009 sales results.

For the third quarter of 2009, the Company recorded net income of $4.2 million, or $0.11 per diluted share, compared to net income for the third quarter of 2008 of $4.2 million, or $0.11 per diluted share. Net income for the third quarter of 2009 included the after-tax effects of approximately $3.3 million of non-cash stock-based compensation expense, $1.6 million of expenses related to the ongoing U.S. governmental inquiries, and $131,000 of restructuring charges related to the previously announced closure of the Company’s Toulon, France operations. Net income for the third quarter of 2008 included the after-tax effects of approximately $3.4 million of non-cash stock-based compensation expense, $1.5 million of expenses related to the ongoing U.S. Governmental inquiries, and $685,000 of restructuring charges related to the previously announced closure of the Company’s Toulon, France operations.

Excluding those items previously mentioned, third quarter net income, as adjusted, totaled $7.6 million in 2009 compared to $7.6 million in 2008, while diluted earnings per share, as adjusted, totaled to $0.19 for both the third quarter of 2009 and 2008. A reconciliation of U.S. GAAP to “as adjusted” results is included in the attached financial tables.

Gary D. Henley, President and Chief Executive Officer commented, “Highlights for the quarter were continued excellent sales performance by our U.S. extremities franchise, significant improvement in our international business, and better than expected foreign currency exchange rates. Together these helped us exceed our top-line guidance range.”

Mr. Henley continued, “We are also pleased with our operational execution again this quarter as excellent expense control and working capital improvement drove adjusted EPS results above our previously communicated earnings outlook range and produced free cash flow of $8.8 million for the quarter. Additionally, we continued to expand the underlying capabilities of our business, including the further expansion of our product portfolios, the enhancement and expansion of our sales force, and the continued improvement of our working capital utilization.”

(Page 2 of 8)

Sales Review

Global net sales of the Company’s extremity, hip, and knee product lines increased by 18%, 7%, and 5%, respectively, while the biologics product line declined 4% during the third quarter of 2009 when compared to the third quarter of 2008.

Domestic sales totaled $73.8 million during the third quarter of 2009, representing an increase of 4% compared to prior year. Domestically, the Company experienced growth in its extremity and knee product lines of 24% and 1%, while its biologics and hip product lines declined 3% and 4%, respectively.

International sales, as reported, were $44.0 million for the third quarter of 2009, representing an increase of 9% compared to prior year, both as reported and constant currency. There was no net impact of foreign currency during the third quarter of 2009.

Outlook

The Company’s earnings targets, as communicated in the guidance ranges stated below for the full year and the fourth quarter of 2009 exclude the effect of possible future acquisitions, other material future business developments, the impact of recording non-cash stock-based compensation and restructuring charges, and costs associated with the Company’s ongoing U.S. governmental inquiries.

The Company has narrowed its sales target for the full year 2009 to a range of $480 million to $485 million, representing the upper end of its previously-communicated guidance range of $475 million to $485 million. This new sales target represents annualized as-reported growth between approximately 3% and 4% and constant-currency growth expectations of approximately 4% to 5%. The Company is also narrowing its previously-communicated as-adjusted earnings per share outlook to a target range for the full year of $0.80 to $0.84 per diluted share compared to its previously communicated guidance range of $0.78 to $0.85 per share.

The Company’s anticipated targets for the fourth quarter of 2009 for net sales are in the range of $122 million to $127 million, representing as-reported sales growth objectives between approximately 2% and 6% and constant-currency growth expectations of approximately 1% to 5%, with as-adjusted earnings per share results ranging from $0.22 to $0.26 per diluted share.

As noted above, the Company’s financial targets exclude the impact of non-cash stock-based compensation charges as well as the impact of restructuring charges. While the amount of the non-cash stock-based compensation charges will vary depending upon a number of factors, many of which not being within the Company’s control, the Company currently estimates that the after-tax impact of those expenses will range from $0.22 to $0.23 per diluted share for the full year 2009 and $0.06 to $0.07 per diluted share for the fourth quarter of 2009. With regard to restructuring charges, the Company has restated its estimate of total pre-tax charges related to the closing of the Toulon facilities to a range of approximately $28 million to $32 million, of which $26.6 million have been incurred to date. Additionally, we anticipate incurring pre-tax restructuring charges related to the change in our French distribution and support model of $4 million to $5 million, with $3 million to $4 million of these charges in the fourth quarter of 2009.

The Company’s anticipated targets for net sales, adjusted earnings per share, stock-based compensation charges and restructuring charges are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from the anticipated targets. The anticipated targets are not predictions of the Company’s actual performance. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.

(Page 3 of 8)

Conference Call

As previously announced, the Company will host a conference call starting at 3:30 p.m. (Central Time) today. The live dial-in number for the call is 866-314-5050 (domestic) or 617-213-8051 (international). The participant passcode for the call is “wright.” To access a simultaneous webcast of the conference call via the internet, go to the “Corporate — Investor Information” section of the Company’s website located at www.wmt.com. A replay of the conference call by telephone will be available starting at 6:30 p.m. (Central Time) today and continuing until November 5, 2009. To hear this replay, dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter the passcode 71198224. A replay of the conference call will also be available via the internet starting today and continuing for at least 12 months. To access a replay of the conference call via the internet, go to the “Corporate — Investor Information - Audio Archives” section of the Company’s website located at www.wmt.com.

The conference call may include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the “Corporate — Investor Information - Supplemental Financial Information” section of the Company’s website located at www.wmt.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as net sales, excluding the impact of foreign currency, operating income, as adjusted, net income, as adjusted, net income, as adjusted, per diluted share, and effective tax rate, as adjusted. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. The measures exclude such items as business development activities, including purchased in-process research and development, the financial impact of significant litigation, costs related to the on-going U.S. governmental inquiries, restructuring charges and non-cash stock-based expense, all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company’s reported results of operations for a period. Management uses these measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe-Harbor Statement

This press release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Such risks and uncertainties include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report onForm 10-K for the year ended December 31, 2008, under the heading, “Risk Factors” and our subsequently filed Exchange Act reports). Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date.

Wright Medical Group, Inc. is a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics. The Company has been in business for more than 50 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company’s website at www.wmt.com.

—Tables Follow—

(Page 4 of 8)

Wright Medical Group, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data—unaudited)

	Three Months Ended					Nine Months Ended
	September 30,		September 30,			September 30,			September 30,
	2009		2008			2009			2008
Net sales	$	117,742	$	111,096		$	357,580		$	345,438
Cost of sales		35,880		32,038			110,646			99,287
Gross profit		81,862		79,058			246,934			246,151
Operating expenses:
Selling, general and administrative		63,703		61,897			196,133			197,361
Research and development		8,537		8,338			26,460			24,715
Amortization of intangible assets		1,274		1,287			3,899			3,604
Restructuring charges		131		685			991			5,595
Acquired in-process research and development		—		—			—			2,490
Total operating expenses		73,645		72,207			227,483			233,765
Operating income		8,217		6,851			19,451			12,386
Interest expense, net		1,435		717			3,974			1,127
Other (income) expense, net		108		(284	)		(358	)		(907	)
Income before income taxes		6,674		6,418			15,835			12,166
Provision for income taxes		2,522		2,231			5,939			6,278
Net income	$	4,152	$	4,187		$	9,896		$	5,888
Net income per share, basic	$	0.11	$	0.11		$	0.27		$	0.16
Net income per share, diluted	$	0.11	$	0.11		$	0.26		$	0.16
Weighted-average number of common shares outstanding, basic		37,431		37,095			37,331			36,845
Weighted-average number of common shares outstanding, diluted		37,551		38,037			37,395			37,536

Wright Medical Group, Inc.
Consolidated Sales Analysis
(dollars in thousands—unaudited)

	Three Months Ended							Nine Months Ended
	September 30,		September 30,		%			September 30,		September 30,		%
	2009		2008		change			2009		2008		change
Geographic
Domestic	$	73,780	$	70,883		4.1	%	$	221,280	$	207,242		6.8	%
International		43,962		40,213		9.3	%		136,300		138,196		(1.4	%)
Total net sales	$	117,742	$	111,096		6.0	%	$	357,580	$	345,438		3.5	%
Product Line
Hip products	$	40,055	$	37,562		6.6	%	$	123,030	$	118,873		3.5	%
Knee products		30,114		28,692		5.0	%		90,727		90,116		0.7	%
Extremity products		25,546		21,706		17.7	%		77,116		64,070		20.4	%
Biologics products		19,437		20,197		(3.8	%)		58,672		61,548		(4.7	%)
Other		2,590		2,939		(11.9	%)		8,035		10,831		(25.8	%)
Total net sales	$	117,742	$	111,096		6.0	%	$	357,580	$	345,438		3.5	%

(Page 5 of 8)

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands—unaudited)

	Three Months Ended				Nine Months Ended
	September 30, 2009				September 30, 2009
	International Net		Total		International Net		Total
	Sales		Net Sales		Sales		Net Sales
Net sales, as reported	$	43,962	$	117,742	$	136,300	$	357,580
Currency impact as compared to prior period		0		0		6,419		6,419
Net sales, excluding the impact of foreign currency	$	43,962	$	117,742	$	142,719	$	363,999

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data—unaudited)

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2009			2008			2009			2008
Operating Income
Operating income, as reported	$	8,217		$	6,851		$	19,451		$	12,386
Reconciling items impacting Gross Profit:
Inventory step-up amortization		10			22			70			95
Non-cash, stock-based compensation		335			300			938			952
Total		345			322			1,008			1,047
Reconciling items impacting Selling, General and Administrative expenses:
Non-cash, stock-based compensation		2,517			2,623			7,822			8,440
U.S. governmental inquiries		1,585			1,546			7,659			4,732
Appellate court decision		—			—			—			2,346
Total		4,102			4,169			15,481			15,518
Reconciling items impacting Research and Development expenses:
Non-cash, stock-based compensation		480			430			1,440			1,096
Other Reconciling Items:
Restructuring charges		131			685			991			5,595
Acquired in-process research and development		—			—			—			2,490
Total		131			685			991			8,085
Operating income, as adjusted	$	13,275		$	12,457		$	38,371		$	38,132
Operating income, as adjusted, as a percentage of net sales		11.3	%		11.2	%		10.7	%		11.0	%

(Page 6 of 8)

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2009			2008			2009			2008
Net Income
Net income, as reported	$	4,152		$	4,187		$	9,896		$	5,888
Pre-tax impact of reconciling items:
Non-cash, stock-based compensation		3,332			3,353			10,200			10,488
Restructuring charges		131			685			991			5,595
Inventory step-up amortization		10			22			70			95
U.S. governmental inquiries		1,585			1,546			7,659			4,732
Appellate court decision (including interest)		—			—			—			2,638
Acquired in-process research and development		—			—			—			2,490
Total		5,058			5,606			18,920			26,038
Tax effect of reconciling items:
Non-cash, stock-based compensation		(968	)		(1,118	)		(3,005	)		(3,098	)
Restructuring charges		(52	)		(437	)		(387	)		(2,167	)
Inventory step-up amortization		(4	)		(9	)		(27	)		(37	)
U.S. governmental inquiries		(624	)		(609	)		(2,997	)		(1,865	)
Appellate court decision		—			—			—			(1,039	)
Acquired in-process research and development		—			—			—			—
Total		(1,648	)		(2,173	)		(6,416	)		(8,206	)
Net income, as adjusted	$	7,562		$	7,620		$	22,400		$	23,720

	Three Months Ended				Three Months Ended
	September 30, 2009				September 30, 2008
	As Reported		As Adjusted		As Reported		As Adjusted
Basic net income	$	4,152	$	7,562	$	4,187	$	7,620
Interest expense on convertible notes		N/A		935		N/A		937
Diluted net income	$	4,152	$	8,497	$	4,187	$	8,557
Basic shares		37,431		37,431		37,095		37,095
Dilutive effect of stock options and restricted shares		120		120		942		942
Dilutive effect of convertible notes		N/A		6,126		—		6,126
Diluted shares		37,551		43,677		38,037		44,163
Net income per share, diluted	$	0.11	$	0.19	$	0.11	$	0.19

(Page 7 of 8)

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Nine Months Ended				Nine Months Ended
	September 30, 2009				September 30, 2008
	As Reported		As Adjusted		As Reported		As Adjusted
Basic net income	$	9,896	$	22,400	$	5,888	$	23,720
Interest expense on convertible notes		N/A		2,805		N/A		2,811
Diluted net income	$	9,896	$	25,205	$	5,888	$	26,531
Basic shares		37,331		37,331		36,845		36,845
Dilutive effect of stock options and restricted shares		64		64		691		691
Dilutive effect of convertible notes		—		6,126		—		6,126
Diluted shares		37,395		43,521		37,536		43,662
Net income per share, diluted	$	0.26	$	0.58	$	0.16	$	0.61

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2009			2008			2009			2008
Net Income per Diluted Share
Net income, as reported, per diluted share	$	0.11		$	0.11		$	0.26		$	0.16
Interest expense on convertible notes		0.02			0.02			0.06			0.06
Dilutive effect of convertible notes		(0.02	)		(0.02	)		(0.04	)		(0.02	)
Non-cash, stock-based compensation		0.05			0.05			0.17			0.17
Restructuring charges		0.00			0.01			0.01			0.08
Inventory step-up amortization		0.00			0.00			0.00			0.00
U.S. governmental inquiries		0.02			0.02			0.11			0.07
Appellate court decision		—			—			—			0.04
Acquired in-process research and development		—			—			—			0.06
Net income, as adjusted, per diluted share	$	0.19		$	0.19		$	0.58		$	0.61

Wright Medical Group, Inc.
Reconciliation of Effective Tax Rate, As Reported, to Effective Tax Rate, As Adjusted
(unaudited)

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2009			2008			2009			2008
Effective tax rate, as reported		37.8	%		34.8	%		37.5	%		51.6	%
Non-cash, stock-based expense		(2.6	%)		(1.3	%)		(2.6	%)		(3.2	%)
Restructuring charges		0.0	%		2.8	%		0.1	%		(4.1	%)
Inventory step-up amortization		0.0	%		0.0	%		0.0	%		0.0	%
U.S. governmental inquiries		0.3	%		0.3	%		0.5	%		(0.3	%)
Appellate court decision		—			—			—			(0.3	%)
Acquired in-process research and development		—			—			—			(5.8	%)
Effective tax rate, as adjusted		35.5	%		36.6	%		35.5	%		37.9	%

(Page 8 of 8)

Wright Medical Group, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands—unaudited)

	September 30,		December 31,
	2009		2008
Assets
Current assets:
Cash and cash equivalents	$	121,234	$	87,865
Marketable securities		40,440		57,614
Accounts receivable, net		110,288		102,046
Inventories		166,339		176,059
Prepaid expenses and other current assets		45,839		53,071
Total current assets		484,140		476,655
Property, plant and equipment, net		137,665		133,651
Goodwill and intangible assets, net		71,497		70,772
Other assets		12,054		11,052
Total assets	$	705,356	$	692,130
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	14,025	$	15,877
Accrued expenses and other current liabilities		52,821		59,247
Current portion of long-term obligations		162		125
Total current liabilities		67,008		75,249
Long-term obligations		200,144		200,136
Other liabilities		3,939		5,117
Total liabilities		271,091		280,502
Stockholders’ equity		434,265		411,628
Total liabilities and stockholders’ equity	$	705,356	$	692,130